KR20220139912A - Brd4 단백질 분해 유도 작용을 갖는 술폰아미드 또는 술핀아미드 화합물 및 그 의약으로서의 용도 - Google Patents

Brd4 단백질 분해 유도 작용을 갖는 술폰아미드 또는 술핀아미드 화합물 및 그 의약으로서의 용도 Download PDF

Info

Publication number
KR20220139912A
KR20220139912A KR1020227030071A KR20227030071A KR20220139912A KR 20220139912 A KR20220139912 A KR 20220139912A KR 1020227030071 A KR1020227030071 A KR 1020227030071A KR 20227030071 A KR20227030071 A KR 20227030071A KR 20220139912 A KR20220139912 A KR 20220139912A
Authority
KR
South Korea
Prior art keywords
group
cyano
methyl
halogen atom
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227030071A
Other languages
English (en)
Korean (ko)
Inventor
기요미 오바
야스키 니와
데츠지 마츠다이라
마이코 하마다
류타 야마자키
다츠야 이부키
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=77199607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220139912(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Publication of KR20220139912A publication Critical patent/KR20220139912A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227030071A 2020-02-06 2021-02-05 Brd4 단백질 분해 유도 작용을 갖는 술폰아미드 또는 술핀아미드 화합물 및 그 의약으로서의 용도 Pending KR20220139912A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-019227 2020-02-06
JP2020019227 2020-02-06
PCT/JP2021/004231 WO2021157684A1 (ja) 2020-02-06 2021-02-05 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Publications (1)

Publication Number Publication Date
KR20220139912A true KR20220139912A (ko) 2022-10-17

Family

ID=77199607

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030071A Pending KR20220139912A (ko) 2020-02-06 2021-02-05 Brd4 단백질 분해 유도 작용을 갖는 술폰아미드 또는 술핀아미드 화합물 및 그 의약으로서의 용도

Country Status (14)

Country Link
US (3) US12102641B2 (https=)
EP (1) EP4105220A4 (https=)
JP (3) JP7419406B2 (https=)
KR (1) KR20220139912A (https=)
CN (1) CN115087658B (https=)
AR (1) AR121275A1 (https=)
AU (1) AU2021215623A1 (https=)
BR (1) BR112022014889A2 (https=)
CA (1) CA3168824C (https=)
IL (1) IL295041A (https=)
MX (1) MX2022009700A (https=)
TW (1) TWI887352B (https=)
WO (1) WO2021157684A1 (https=)
ZA (1) ZA202209896B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7419406B2 (ja) 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
JP2022123408A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123894A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP2022123407A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123893A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP7852736B2 (ja) * 2022-10-28 2026-04-28 株式会社村田製作所 電子部品および電子部品の実装構造
WO2024251876A1 (en) * 2023-06-07 2024-12-12 KRæFTENS BEKæMPELSE PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体
CN120865239B (zh) * 2025-09-25 2025-12-12 深圳大学 基于苯并咪唑融合共价弹头的降解剂及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
JP2801500B2 (ja) 1993-07-02 1998-09-21 株式会社トクヤマ Ｎ−アルコキシカルボニルアミノ酸の製造方法
CN1109037C (zh) 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
CN109503618A (zh) * 2017-09-14 2019-03-22 成都海创药业有限公司 一种brd4抑制剂
EP3723757A4 (en) 2017-12-14 2021-08-18 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE TYPE DEGRADATION AGENTS RECRUITING DCAF15
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity
EP3819305A4 (en) * 2018-07-04 2022-04-06 Mitsubishi Tanabe Pharma Corporation AMIDE COMPOUND WITH BET PROTEOLYSIS-INDUCING ACTIVITY AND MEDICAL USE THEREOF
JP7140273B2 (ja) 2019-04-09 2022-09-21 株式会社村田製作所 電池
JP7419406B2 (ja) * 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
Crawford NP., Proc Natl Acad Sci U S A. 2008, 105: 6380-6385
Dai X., Nat Med. 2017, 23: 1063-1071
Dai X., Nat Med. 2017, 23:1063-1071
Herrmann H., Oncotarget. 2012, 3: 1588-1599
Hu Y., Int J Mol Sci. 2015, 16:1928-1948
Iliopoulos O., Nat Med. 1995, 1:822-826.
Kanno T., Nat Struct Mol Biol. 2014, 21: 1047-1057
Li L., Signal Transduct Target Ther. 2020, 5: 129.
Liao YF., Oncotarget. 2016, 7: 9491-9500
Liu Z., J Med Chem. 2017, 60: 4533-4558
Lu J., Chem Biol. 2015, 22: 755-763
Neil V., Nature. 2019, 575: 299-309
Raina K., Proc Natl Acad Sci U S A. 2016, 113: 7124-7129
Schapira M., Nat Rev Drug Discov. 2019, 18: 949-963.
Segura MF., Cancer Res. 2013, 73:6264-6276
Shu S., Nature. 2016, 529: 413-417
Stathis A., Cancer Discov. 2016, 6: 492-500
Taniguchi Y., Int J Mol Sci. 2016, 17:E1849
Toure M., Angew Chem Int Ed Engl. 2016, 55: 1966-1973
Ucar D., Mol Clin Oncol. 2015, 3: 1291-1294
Yan Y., Int J Clin Exp Pathol. 2014, 7: 4231-4238
Zhang L., Mol Cancer Ther. 2019, 18: 1302-1311.
Zhang P., Int J Immunopathol Pharmacol. 2015, 28: 36-44
Zhu Y., Oncotarget. 2017, 8: 31092-31100

Also Published As

Publication number Publication date
US20230146717A1 (en) 2023-05-11
TWI887352B (zh) 2025-06-21
ZA202209896B (en) 2025-12-17
MX2022009700A (es) 2022-09-07
US12102641B2 (en) 2024-10-01
WO2021157684A1 (ja) 2021-08-12
EP4105220A4 (en) 2024-02-21
IL295041A (en) 2022-09-01
AU2021215623A1 (en) 2022-08-25
CA3168824C (en) 2024-10-22
TW202140498A (zh) 2021-11-01
US20230364105A1 (en) 2023-11-16
AR121275A1 (es) 2022-05-04
CN115087658B (zh) 2025-02-28
JPWO2021157684A1 (https=) 2021-08-12
JP2024041888A (ja) 2024-03-27
JP7419406B2 (ja) 2024-01-22
CA3168824A1 (en) 2021-08-12
EP4105220A1 (en) 2022-12-21
JP2025122015A (ja) 2025-08-20
CN115087658A (zh) 2022-09-20
US11890288B2 (en) 2024-02-06
JP7681737B2 (ja) 2025-05-22
BR112022014889A2 (pt) 2022-09-20
US20240390387A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
KR20220139912A (ko) Brd4 단백질 분해 유도 작용을 갖는 술폰아미드 또는 술핀아미드 화합물 및 그 의약으로서의 용도
CN114040914B (zh) 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN105008352B (zh) 用作溴区结构域抑制剂的咔唑化合物
US11542273B2 (en) Amide compound having bet proteolysis-inducing action and medicinal application thereof
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN117800989A (zh) 一类含环外双键、多取代甲基醚结构的化合物及其应用
WO2008147713A1 (en) Wnt signaling inhibitors, and methods for making and using them
EA038164B1 (ru) 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
CN112028870B (zh) 一种具有苄氧基芳环结构的化合物，其制备方法和用途
BR112021007602A2 (pt) compostos de heteroaril carboxamida de 5 membros para tratamento de hbv
CN114409656A (zh) Pim激酶抑制剂
JP7614145B2 (ja) Ｂｒｄ４蛋白質分解誘導剤を含む医薬
CN110483366B (zh) 吲哚类化合物及其制备方法、药物组合物和用途
WO2024149189A1 (zh) 芳香酰胺类衍生物及其制备方法和用途
CN105358544A (zh) 杂环化合物
RU2830112C1 (ru) Соединение сульфонамида или сульфинамида, обладающее эффектом индуцирования деградации белка brd4, и его применение в медицине
JP2019522014A (ja) インドリン誘導体
WO2024188086A1 (zh) 芳香酰胺类衍生物及其制备方法和用途
CN115724784A (zh) 作为p53调节剂和/或hdac抑制剂的化合物
HK40080729A (en) Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof
WO2017096648A1 (zh) Plk1抑制剂及其制备方法与应用
WO2019092044A1 (en) Dihydrobenzo[b][1]benzothiepin compounds useful in therapy
TW201444828A (zh) 可作爲溴區結構域蛋白抑制劑之咔唑化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000